Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Dig Dis Sci. 2020 Sep 7;66(9):3186–3191. doi: 10.1007/s10620-020-06588-6

Table 1.

Patient characteristics in all IBD patients and those with NAFLD at index and at 5-year follow-up

Demographics All IBD patients (n = 1672) IBD patients with NAFLD (n = 207) IBD patients with NAFLD and index NFS (n = 138) IBD patients with NAFLD and 5-year follow-up (n = 56)
Sex, n (%)
 Male 752 (45) 96 (46) 68 (49) 25 (45)
 Female 920 (55) 111 (54) 70 (51) 31 (55)
Mean age (y ± SD)  48 ± 15.6 50.6 ± 13.6 49.6 ± 13.3 52.1 ± 12.4
BMI (mean ± SD), n (%) 25.9 ± 6.8 29.5 ± 8 29.7 ± 7.8 30.8 ± 8.3
 Underweight < 18.5 54 (3) 12 (6) 7 (5) 2 (3)
 Normal 18.5–24.9 420 (25) 42 (20) 33 (24) 11 (20)
 Overweight 25–29.9 245 (15) 42 (20) 32 (23) 19 (34)
 Obese > 30 213 (13) 79 (38) 66 (48) 24 (43)
 Blank 740 (44) 32 (16) 0 (0) 0 (0)
Race, n (%)
 Caucasian 1325 (79) 162 (78) 105 (76) 42 (75)
 African-American 260 (16) 35 (17) 26 (19) 13 (23)
 Asian 51 (3) 3 (2) 2 (1) 1 (2)
 Other 36 (2) 7 (3) 5 (4) 0 (0)
IBD type, n (%)
 Crohn’s disease 897 (55) 131 (63) 86 (62) 39 (70)
 Ulcerative colitis 453 (27) 39 (19) 24 (17) 10 (18)
 Undetermined type 67 (4) 9 (4) 5 (4) 0 (0)
 Microscopic 30 (1) 3 (1) 0 (0) 0 (0)
 Eosinophilic 1 (0) 0 (0) 0 (0) 0 (0)
 Unclassified 224 (13) 26 (13) 23 (17) 7 (12)
Medication history, n (%)
 5-ASA use 334 (20) 36 (17) 23 (17) 10 (18)
 Immunosuppressant use 790 (47) 106 (51) 65 (47) 35 (63)
 Biologic use 745 (45) 116 (56) 75 (54) 37 (66)